Associate Director, Clinical Biomarkers (Oncology)

BeOne Medicines; United States; Vor Ort; USD 147.000 - 197.000; Vollzeit

Benefits dieser Stelle

Equity awards

Employee Stock Purchase Plan

Comprehensive benefits

Zusammenfassung

BeOne Medicines is seeking an Associate Director of Clinical Biomarker & Translational Medicine for Oncology (Solid Tumor Portfolio, GI franchise) to lead biomarker strategies across our clinical programs.

You will oversee assay development, trial biomarkers, and regulatory contributions while mentoring teams and collaborating with external partners to accelerate oncology drug development.

Qualifikationen

• PhD or MD/PhD in a relevant scientific discipline with 5+ years in pharma/biotech biomarker science in oncology.
• Deep expertise in biomarker discovery, clinical assay development, and validation for oncology trials.
• Proven leadership in translational medicine with biomarker strategies leading to regulatory milestones.

Aufgaben

• Lead global clinical biomarker strategy for solid tumor oncology with cross-functional teams.
• Oversee biomarker assay development, design input, and analytical/clinical validation.
• Analyze biomarker data to inform go/no-go decisions and trial progression.
• Communicate biomarker insights to internal and external stakeholders to shape strategy.
• Drive external partnerships with academia, CROs, and industry to advance biomarker programs.

Kenntnisse

Biomarker strategy

Clinical biomarker development

Translational medicine leadership

Cross-functional collaboration

Regulatory submissions

Publications / regulatory contributors

Mentoring / team leadership

Ausbildung

PhD or MD/PhD

Jobbeschreibung

BeOne Medicines is seeking an Associate Director of Clinical Biomarker & Translational Medicine for Oncology (Solid Tumor Portfolio, GI franchise) to lead biomarker strategies across our clinical programs.

You will oversee assay development, trial biomarkers, and regulatory contributions while mentoring teams and collaborating with external partners to accelerate oncology drug development.